Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501666 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

286

Enrollment

INDUSTRY

Sponsor class

Conditions

Prurigo Nodularis

Interventions

DRUG: Nemolizumab 30 mg
DRUG: Placebo

Sponsor

Galderma R&D